patent.fyi
Applications  /  US 2026/0355323
United States Patent Application Publication

US 2026/0355323 A1

Published
Nov 12, 2026
Filed
Oct 3, 2023
Earliest date on the face
Oct 3, 2022
Classification
A61K 47/55
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Methylthio group at R1

What ifWhat if R1 connects its methyl group to the core through sulfur?
Claim language“—O(substituted or unsubstituted alkyl)”

A methylthio group uses a core–S–CH3 linkage. The larger sulfur atom gives the core-to-methyl linkage a longer bond path than an ether linkage.

1.2Open chain nitrogen substituents

What ifWhat if the nitrogen carries separate methyl and cyclopropyl groups with no ring closure through the nitrogen?
Claim language“joined with the nitrogen atom to which they are attached”

The nitrogen forms three bonds, one to the core, one to methyl carbon, and one to cyclopropyl carbon. The cyclopropyl ring constrains its own carbon framework while rotation about the nitrogen-to-cyclopropyl bond remains available.

1.3Cyano group at R2

What ifWhat if R2 is a cyano group attached directly through its carbon atom?
Claim language“SO2CF3 or NO2”

The nitrile withdraws electron density through the attached scaffold and presents a terminal nitrogen as a hydrogen-bond acceptor. The carbon–nitrogen triple bond keeps the substituent linear.

1.7Ether oxygen at Z

What ifWhat if Z is a single ether oxygen between two carbon attachment points?
Claim language“a bond, CH2, or CO”

The oxygen forms a C–O–C bridge that joins the two fragments through a bent linkage. The ether oxygen supplies a hydrogen-bond acceptor at the junction.

1.8Thiocarbonyl bridge at Y

What ifWhat if Y uses a thiocarbonyl group with sulfur double-bonded to the bridge carbon?
Claim language“is CO”

The C=S group retains a trigonal planar bridge carbon and the two attachment bonds to the surrounding fragments. The larger sulfur atom extends farther from the bridge carbon than oxygen in a carbonyl.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Comparative testing in canine tumor cultures

The cereblon-recruiting dual degrader serves as a research reagent in canine lymphoma cell cultures. Matched wells receive the degrader, its unconjugated target-binding ligand, or vehicle. Immunoblotting with antibodies validated for canine BCL-XL and BCL-2 measures the abundance of both proteins, and a parallel viability assay measures the cellular response.

Component substitution

Cyclohexane spacer in the central linker

A trans-1,4-cyclohexanediyl unit replaces a flexible hexamethylene segment at L2. The two adjoining linker segments attach at opposite ring carbons in the trans configuration, connecting the target-binding and cereblon-binding ends through a conformationally restricted spacer. A matched pair of compounds with the same terminal ligands and different L2 segments is tested for depletion of BCL-XL and BCL-2.

Parameter or scale variation

Linker length series with timed sampling

Three compounds use straight saturated L1 segments with 3, 5, or 7 backbone carbons and share the same L2, L3, and terminal ligands. Replicate cell cultures receive each compound at 10, 100, and 1000 nanomolar. Samples collected at 2, 6, and 24 hours provide separate BCL-XL and BCL-2 measurements normalized to time-matched vehicle controls.

Combination with existing systems

Perfused tumor spheroid exposure system

A microfluidic culture chip holds tumor spheroids in chambers connected to a medium inlet and an effluent outlet. A syringe pump passes degrader-containing medium through the chambers during exposure and switches to compound-free medium for washout. Individual spheroids are collected at defined intervals and lysed for separate measurements of BCL-XL and BCL-2 during exposure and recovery.

Paired live-cell luminescence degradation assay

Two matched reporter cell lines carry a small luminescence-complementing peptide tag on endogenous BCL-XL or BCL-2, respectively. The degrader is added to both lines in parallel, and the tag signal is measured after addition of the complementary enzyme fragment and substrate. A time series normalized to vehicle wells tracks the abundance of each tagged protein, and immunoblotting in the unmodified parental line checks that the tags preserve the depletion response.

Automated or data-driven variant

Automated selection of follow-up concentrations

A liquid handler dispenses the dual degrader across a concentration series in multiwell plates and distributes vehicle controls across each plate. Software processes immunoassay signals for BCL-XL and BCL-2 from matched wells, normalizes them to the vehicle controls, and fits a separate concentration-response curve for each protein. The software generates a second plate layout with additional concentrations around each estimated half-maximal depletion point and extends the concentration range when the initial measurements fail to bracket that point.

Specific version of a part

Fluorine and methoxy substituents

At n1 = 2, one R4 site carries fluorine and the other carries methoxy. Fluorine bonds directly to the scaffold, and methoxy attaches through oxygen in a scaffold–O–CH3 linkage.

One R4 substitution site

Set n1 to 1 and place chlorine at the single R4 site. The chlorine forms one direct bond to the scaffold.

Methyl group at R7

An unsubstituted methyl group occupies the R7 position. Its carbon forms one single bond to the attachment atom and carries three hydrogens.

Four carbon L2 segment

L2 consists of four consecutive methylene groups, with one attachment at each end. The three internal carbon–carbon single bonds allow the segment to sample extended and bent conformations.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2011/0124627 A1
Published
May 26, 2011
Filed
Sep 10, 2010
Class
A61K 31/397
Document BUS 10,189,788 B2
Published
Jan 29, 2019
Filed
Sep 7, 2015
Class
C07D 215/52
Claim 1
Document A
Document B
1.1R1 is —O(substituted or unsubstituted alkyl) or —N(Ra)2
D is aryl or heteroaryl; is 0, 1, or 2; each R3 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(
A · US 2011/0124627 A1 · ¶
in which RA is hydrogen, halogen, pentafluorosulfanyl, cyano, nitro, (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy, amino or a group of the formula —NH—C(═O)—R6, —NH—C(═O)—NH—R6 or —S(═O)n—R7, where (C1-C4)-alkyl and (C1-C4)-alkoxy may be up to trisubstituted by fluorine, and in which R6 is hydrogen or (C1-C4)-alkoxy which may be up to trisubstituted by fluorine, R7 is (C1-C4)-alkyl which may be substituted by hydroxyl, methoxy or ethoxy or up to trisubstituted by fluorine, and n i
B · US 10,189,788 B2 · ¶ 19
1.2wherein each instance of Ra is independently substituted or unsubstituted alkyl or substituted or unsubstituted carbocyclyl, or two instances of Ra are joined with the nitrogen atom to which they are attached to form substituted or unsubstituted heterocyclyl
R2 is —NR6R7; and each of R6 and R7 independently is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or toget
A · US 2011/0124627 A1 · ¶
1.3R2 is SO2CF3 or NO2
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates and
B · US 10,189,788 B2 · ¶ 65
1.4R3 is wherein Rb is halogen or substituted or unsubstituted alkyl
D is aryl or heteroaryl; is 0, 1, or 2; each R3 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(
A · US 2011/0124627 A1 · ¶
1.5each instance of R4 is independently F, Cl, —CN, —CFH2, —CF2H, —CF3, or —OCH3
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates and
B · US 10,189,788 B2 · ¶ 65
1.6n1 is 0, 1, 2, or 3
1.7Z is a bond, CH2, or CO
1.8Y is CO
1.9or wherein R6 is F, Cl, CN, CFH2, —CF2H, —CF3, —OCH3, or H
Z is H, halogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cyano, azido, —C(O)H, —C(O)R8, —S(O)R8, —S(O)2R8, —S(O)2NR8R9, —C(O)OR8, or —C(O)NR9R10;
A · US 2011/0124627 A1 · ¶
A particular embodiment of the present invention comprises compounds of the formula (I) in which RA is hydrogen, fluorine, chlorine, bromine, cyano, nitro, methyl, trifluoromethyl, hydroxyl, methoxy, trifluoromethoxy or a group of the formula —S(═O)n—R7 in which R7 is methyl or trifluoromethyl, and n is the number 0 or 2, D is C—RD or N, in which RD is hydrogen or fluorine, E is C—H and G is C—RG or N, in which RG is hydrogen, fluorine or chlorine, and the salts, solvates and
B · US 10,189,788 B2 · ¶ 65
1.10R7 is H or substituted or unsubstituted alkyl
R2 is —NR6R7; and each of R6 and R7 independently is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or toget
A · US 2011/0124627 A1 · ¶
1.11L1 is substituted or unsubstituted, C1-11 alkylene, substituted or unsubstituted, C2-11 alkenylene, substituted or unsubstituted, C2-11 alkynylene, or substituted or unsubstituted heterocyclylene, optionally wherein one or more backbone carbon atoms in the substituted or unsubstituted, C1-11 alkylene, substituted or unsubstituted, C2-11 alkenylene, or substituted or unsubstituted, C2-11 alkynylene are independently replaced with —O—, —NR5—, ═N—, —N═, —S—, —S(═O)—, —S(═O)2—, —C(═O)—, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, substituted or unsubstituted carbocyclylene, or substituted or unsubstituted arylene
each L2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocycylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, arylene-alkylene, heteroarylene-alkylene, arylene-heteroalkylene, substituted arylene-heteroalkylene, heteroarylene-heteroalkylene, substituted he
A · US 2011/0124627 A1 · ¶ 14
1.12each instance of R5 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl L2 is substituted or unsubstituted, C1-12 alkylene, substituted or unsubstituted, C2-12 alkenylene, substituted or unsubstituted, C2-12 alkynylene, substituted or unsubstituted heterocyclylene, or substituted or unsubstituted carbocyclylene, optionally wherein one or more backbone carbon atoms in the substituted or unsubstituted, C1-12 alkylene, substituted or unsubstituted, C2-12 alkenylene, or substituted or unsubstituted, C2-12 alkynylene are independently replaced with —O—, —NR5—, ═N—, —N═, —S—, —S(═O)—, —S(═O)2—, —C(═O)—, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, substituted or unsubstituted carbocyclylene, or substituted or unsubstituted arylene L3 is a bond, substituted or unsubstituted, C1-13 alkylene, substituted or unsubstituted, C2-13 alkenylene, substituted or unsubstituted, C2-13 alkynylene, or substituted or unsubstituted heterocyclylene, optionally wherein one or more backbone carbon atoms in the substituted or unsubstituted, C1-13 alkylene, substituted or unsubstituted, C2-13 alkenylene, or substituted or unsubstituted, C2-13 alkynylene are independently replaced with —O—, —NR5—, ═N—, —N═, —S—, —S(═O)—, —S(═O)2—, —C(═O)—, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, substituted or unsubstituted carbocyclylene, or substituted or unsubstituted arylene.
each L2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocycylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, arylene-alkylene, heteroarylene-alkylene, arylene-heteroalkylene, substituted arylene-heteroalkylene, heteroarylene-heteroalkylene, substituted he
A · US 2011/0124627 A1 · ¶ 14

An empty cell means only that no passage was reproduced there.

Statements in these documents
This application relates generally to 3-deazapteridinone derivatives and pharmaceutical compositions which selectively modulate toll-like receptors (such as TLR-7), and methods of making and using such compounds.
A · US 2011/0124627 A1 · ¶ 2
The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
B · US 10,189,788 B2 · ¶ 2
These findings show that the FP receptor is a therapeutic target protein for treatment of IPF [Olman, Nat.
B · US 10,189,788 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355323 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355323/, SHA-256 bb3b0021a1f92b699526e4b14f85a87103c056e4a3074eebf81d0249e0b76964
First published
Permanent addresshttps://patent.fyi/US20260355323/
Content fingerprint (SHA-256)bb3b0021a1f92b699526e4b14f85a87103c056e4a3074eebf81d0249e0b76964
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi